Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1)
Status:
Completed
Trial end date:
2021-04-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to to assess the safety and tolerability of pirfenidone 2403
mg/day for the treatment of RA-associated interstitial lung disease.